Earnings ·
iBio Reports Q1 Fiscal 2027 Revenue of $1.1 Million and Net Loss of $7.6 Million
IBIOiBio, Inc.
iBio reported revenue of approximately $1.1 million for the quarter ended September 30, 2026, compared to $0.1 million in the prior year period. The company incurred a net loss of $7.6 million, driven by research and development expenses that rose to $6.7 million from $3.6 million as it advanced clinical trials for IBIO-600 and preclinical work on IBIO-610. General and administrative expenses increased slightly to $2.8 million. Cash and cash equivalents held at quarter-end were approximately $76.7 million. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases.